LexBio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

LexBio General Information

Description

Developer of a drug discovery platform designed to accelerate the development of innovative medicines. The company's platform utilizes deep learning algorithms and professional databases to perform target screening, molecular optimization, and candidate compound generation, enabling biopharmaceutical companies to identify differentiated medicines and reduce experimental costs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 409, 4th Floor, Building C17, Phase I Biomedical Industrial Park
  • Number 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 139
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Corporate Office
  • Room 409, 4th Floor, Building C17, Phase I Biomedical Industrial Park
  • Number 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 139

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LexBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 03-Sep-2026 Completed Generating Revenue
3. Early Stage VC 10-Oct-2023 Completed Generating Revenue
2. Early Stage VC 28-Mar-2023 Completed Generating Revenue
1. Seed Round 19-Apr-2021 Completed Generating Revenue
To view LexBio’s complete valuation and funding history, request access »

LexBio Patents

LexBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026158438-A1 Pentacyclic derivative, and preparation method therefor and use thereof Pending 24-Jan-2025
AU-2025250225-A1 A pyrrolo [2, 3-b] pyridine derivative, and preparation method therefor and use thereof Pending 01-Apr-2024
WO-2025209278-A1 A pyrrolo [2, 3-b] pyridine derivative, and preparation method therefor and use thereof Pending 01-Apr-2024
US-20260028352-A1 Macrocyclic imidazo [1,2-b] pyridazine derivative, preparation method therefor, and use thereof Pending 07-Sep-2022
AU-2023339247-A1 Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof Active 07-Sep-2022 C07D498/22
To view LexBio’s complete patent history, request access »

LexBio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Leader Venture Capital Growth/Expansion Minority
Ascentage Pharma Corporation Minority
Grains Valley Venture Capital Venture Capital Minority
Suzhou Oriza Holdings Corporation Asset Manager Minority
To view LexBio’s complete investors history, request access »

LexBio FAQs

  • When was LexBio founded?

    LexBio was founded in 2021.

  • Where is LexBio headquartered?

    LexBio is headquartered in Suzhou, China.

  • What industry is LexBio in?

    LexBio’s primary industry is Drug Discovery.

  • Is LexBio a private or public company?

    LexBio is a Private company.

  • What is LexBio’s current revenue?

    The current revenue for LexBio is .

  • Who are LexBio’s investors?

    Leader Venture Capital, Ascentage Pharma, Grains Valley Venture Capital, and Suzhou Oriza Holdings Corporation have invested in LexBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process